SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022.

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SANTA CLARA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2022 after market close on Monday, November 7, 2022. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Third Quarter 2022 Financial Results on November 7, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Si-Bone (SIBN) Have the Potential to Rally 42% as Wall Street Analysts Expect?

SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management will be hosting a fireside chat presentation on Wednesday, September 14th, 2022, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

The mean of analysts' price targets for Si-Bone (SIBN) points to a 49.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Matt Bacso - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Craig Bijou - Bank of America David Rescott - Truist Securities Andrew Ranieri - Morgan Stanley David Turkaly - JMP Securities Operator Good afternoon, and welcome to SI-BONE's Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode.

SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2022 Results - Earnings Call Transcript

SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2022.

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022

Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for

SANTA CLARA, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2022 after market close on Monday, August 8, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022

Use Includes Pelvic Fragility Fractures Use Includes Pelvic Fragility Fractures

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SANTA CLARA, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System (Granite). The Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion.

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology

SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Matt Basco - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley Gibran Ahmed - Canaccord David Rescott - Truist Securities David Saxon - Needham Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc.'s (SIBN) CEO Laura Francis on Q1 2022 Results - Earnings Call Transcript

SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2022.

SI-BONE, Inc. Reports First Quarter 2022 Financial Results

Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline

SANTA CLARA, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the Centers for Medicare and Medicaid Services (CMS) has proposed a New Technology Add-on Payment (NTAP) for the iFuse Bedrock Granite™ implant. The Granite implant is intended to provide sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. The Granite implant was awarded Breakthrough Device Designation by the FDA and is anticipated to receive regulatory clearance this year. In designating the Granite implant as a Breakthrough Device, the FDA determined that it provides for more effective treatment of an irreversibly debilitating condition than the current standard of care. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to such innovative technologies for Medicare beneficiaries.

SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2022 Bank of America Healthcare Conference in Las Vegas. Management will be hosting a fireside chat presentation on Wednesday, May 11th, 2022, at 12:40 p.m. Pacific Time / 3:40 p.m. Eastern Time.

SI-BONE To Present at BofA Securities 2022 Healthcare Conference

SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript

SANTA CLARA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2021.

SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance

SANTA CLARA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced management is scheduled to participate in the following investor conference:

SI-BONE to participate in 24th Annual Needham Virtual Growth Conference

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. “We are pleased to welcome these two transformational business leaders as new independent directors on the Board,” said David Brabazon, Chairman of the Mainstay Board of Directors. “Their deep experience will be invaluable to Mainstay as we grow

Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence

SI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence Street Opinion, and New Coverage Policies from Arkansas Blue Cross Blue Shield and Walmart Plans from BlueAdvantage Administrators of Arkansas

SI-BONE's (SIBN) CEO Laura Francis on Q3 2021 Results - Earnings Call Transcript

SANTA CLARA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2021.

News for SI-BONE Inc Stock (SIBN)